A panel of the New Orleans-based 5th U.S. Circuit Court of Appeals has issued a ruling that blocks the mailing of the abortion pill mifepristone, requiring that the drug be distributed only in-person at clinics. The decision was reported by multiple outlets on the same day.
The ruling directly affects access to mifepristone, a medication used in medication abortions. According to the BBC, medication abortion is currently the most common method for the procedure in the United States. By prohibiting mail-order prescriptions, the court's action means that patients seeking the drug will now need to visit a clinic in person to obtain it, rather than receiving it through the mail.
The Newsmax report noted that the ruling sets the stage for a potential Supreme Court case. The PBS Newshour described the court's action as requiring that the abortion pill be distributed only in-person at clinics. The BBC characterized the decision as curbing access to the drug used in medication abortions.
The legal battle over mifepristone access has been ongoing, and this latest ruling from the 5th Circuit adds a new restriction. The requirement for in-person distribution at clinics marks a change from previous practices that had allowed mailing of prescriptions. The case may now proceed to the nation's highest court, as indicated by the Newsmax report.
The decision does not ban mifepristone outright but imposes a logistical barrier by eliminating mail-order delivery. The impact is expected to be felt across the country, as the ruling applies nationwide. Further legal developments are anticipated as the case potentially moves toward the Supreme Court.
Wir bewerten keine Wahrheit. Wir entfernen den Spin und zeigen Ihnen, welche Perspektiven die Geschichte abgedeckt haben. Sie entscheiden.
Originale Berichterstattung lesen
💬 Kommentare
📜 Kommentar-Richtlinie